AstraZeneca (NASDAQ:AZN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on January 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in AstraZeneca stock on December 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
• Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

AstraZeneca Trading Up 1.9%

Shares of AZN stock traded up $1.83 on Wednesday, reaching $96.34. The company had a trading volume of 7,708,501 shares, compared to its average volume of 6,734,095. The stock has a market cap of $298.79 billion, a PE ratio of 32.01, a PEG ratio of 1.55 and a beta of 0.34. The company has a 50-day moving average of $90.82 and a 200-day moving average of $82.40. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $96.51.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. The firm had revenue of $15.19 billion during the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.08 earnings per share. On average, equities analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Primecap Management Co. CA boosted its stake in shares of AstraZeneca by 1.3% during the 2nd quarter. Primecap Management Co. CA now owns 41,200,091 shares of the company’s stock worth $2,879,062,000 after buying an additional 538,606 shares during the last quarter. Bank of America Corp DE raised its holdings in AstraZeneca by 4.7% during the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after acquiring an additional 1,461,786 shares in the last quarter. Franklin Resources Inc. boosted its position in AstraZeneca by 0.9% during the second quarter. Franklin Resources Inc. now owns 21,298,394 shares of the company’s stock valued at $1,488,332,000 after purchasing an additional 196,401 shares during the last quarter. Fisher Asset Management LLC grew its stake in AstraZeneca by 2.3% in the third quarter. Fisher Asset Management LLC now owns 21,162,724 shares of the company’s stock valued at $1,623,604,000 after purchasing an additional 466,745 shares in the last quarter. Finally, Jennison Associates LLC increased its position in shares of AstraZeneca by 15.2% during the 2nd quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock worth $850,255,000 after purchasing an additional 1,605,133 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

AZN has been the subject of several recent analyst reports. Jefferies Financial Group assumed coverage on AstraZeneca in a report on Monday, October 27th. They issued a “buy” rating for the company. Guggenheim reissued a “buy” rating on shares of AstraZeneca in a research note on Wednesday, December 3rd. HSBC reaffirmed a “buy” rating and issued a $108.00 price target on shares of AstraZeneca in a research note on Wednesday, December 10th. Morgan Stanley reiterated an “overweight” rating and issued a $103.00 price target on shares of AstraZeneca in a report on Wednesday, December 3rd. Finally, Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $95.75.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.